{"id":9160,"date":"2025-11-25T10:21:13","date_gmt":"2025-11-25T04:51:13","guid":{"rendered":"https:\/\/chiralpedia.com\/blog\/?p=9160"},"modified":"2025-11-25T13:25:18","modified_gmt":"2025-11-25T07:55:18","slug":"chiral-drug-engineering-designing-safer-smarter-and-more-selective-medicines","status":"publish","type":"post","link":"https:\/\/chiralpedia.com\/blog\/chiral-drug-engineering-designing-safer-smarter-and-more-selective-medicines\/","title":{"rendered":"Chiral Drug Engineering: Building Safer, Smarter, and More Selective Medicines"},"content":{"rendered":"\n<p class=\"has-vivid-red-color has-text-color has-link-color wp-elements-615d5df3060ef9e7ce8353f1ec0c1355\"><em>Where a molecule\u2019s handedness meets clever engineering\u2014shaping safer, more precise, and more effective medicines.<\/em><\/p>\n\n\n\n<p class=\"has-ast-global-color-0-color has-text-color has-link-color has-medium-font-size wp-elements-6eb97d64e44cf3851939a34f30c3f906\"><strong>Introduction: Why Chirality Matters in Drug Engineering<\/strong><\/p>\n\n\n\n<p>In the world of drug design, a subtle twist in molecular geometry can change everything. Two molecules may share the same atoms and bonding pattern yet behave like entirely different substances simply because they are arranged as non-superimposable mirror images\u2014<strong>enantiomers<\/strong>. This property, known as <strong>chirality<\/strong>, is one of the most critical yet nuanced dimensions of pharmaceutical science.<\/p>\n\n\n\n<p>The human body\u2014its enzymes, receptors, transporters, and nucleic acids\u2014is inherently <strong>chiral<\/strong>. As a result, when a chiral drug enters the body, the left-handed (S- or L-form) and right-handed (R- or D-form) versions may be absorbed differently, bind receptors differently, get metabolized differently, or even trigger opposite physiological responses. One enantiomer may be therapeutic, while the other may be inactive, antagonistic, or in some cases, toxic.<\/p>\n\n\n\n<p><strong>Chiral drug engineering<\/strong> is the systematic approach to harnessing this stereochemical complexity. It involves designing, synthesizing, isolating, and optimizing specific enantiomers\u2014either as <strong>single-enantiomer drugs<\/strong> or as <strong>chiral switches<\/strong> derived from racemic (50:50) precursors\u2014to improve safety, potency, and performance. Over the past three decades, it has evolved into a cornerstone of rational drug design.<\/p>\n\n\n\n<figure class=\"wp-block-image aligncenter size-large is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"797\" src=\"https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/11\/Chiral-Drug-Engineering-1024x797.png\" alt=\"\" class=\"wp-image-9226\" style=\"width:610px;height:auto\" srcset=\"https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/11\/Chiral-Drug-Engineering-1024x797.png 1024w, https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/11\/Chiral-Drug-Engineering-300x233.png 300w, https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/11\/Chiral-Drug-Engineering-768x597.png 768w, https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/11\/Chiral-Drug-Engineering-1536x1195.png 1536w, https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/11\/Chiral-Drug-Engineering.png 1585w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p class=\"has-ast-global-color-0-color has-text-color has-link-color has-medium-font-size wp-elements-e96aa8bde7be9e10cad8d8a0fde2d358\"><strong>From Racemates to Single Enantiomers: A Paradigm Shift<\/strong><\/p>\n\n\n\n<p>For much of pharmaceutical history, synthesizing pure enantiomers was difficult, expensive, and technically limiting. As a result, many blockbuster drugs of the 20th century were launched as <strong>racemic mixtures<\/strong>\u2014equal parts left- and right-handed molecules. Classic examples include ibuprofen, warfarin, thalidomide, albuterol, and omeprazole.<\/p>\n\n\n\n<p>But with advances in stereoselective chemistry and analytical capabilities, the industry began shifting toward <strong>single-enantiomer therapeutics<\/strong>. The motivation was multifold:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Enhanced safety:<\/strong> Eliminating a harmful or reactive enantiomer.<\/li>\n\n\n\n<li><strong>Improved efficacy:<\/strong> Delivering only the pharmacologically active molecule.<\/li>\n\n\n\n<li><strong>Lower dose requirements:<\/strong> Reducing metabolic burden and side effects.<\/li>\n\n\n\n<li><strong>Patent advantage:<\/strong> Extending product lifecycle via chiral switching.<\/li>\n<\/ul>\n\n\n\n<p>The 1990s and 2000s marked the era of <strong>\u201cchiral switches\u201d<\/strong>\u2014transforming racemic drugs into purified enantiomers. Esomeprazole (from omeprazole), levocetirizine (from cetirizine), escitalopram (from citalopram), and levalbuterol (from albuterol) are textbook examples.<\/p>\n\n\n\n<p>This movement was reinforced by regulatory shifts. The FDA\u2019s 1992 guideline on stereochemical issues recommended enantiomer-specific evaluation, effectively mainstreaming chiral drug engineering.<\/p>\n\n\n\n<h2 class=\"wp-block-heading has-ast-global-color-0-color has-text-color has-link-color has-medium-font-size wp-elements-bebf4bfb57410d941fa0c51e38af2bcd\"><strong>The Science Behind Enantiomeric Differences<\/strong> <strong>in chiral drugs<\/strong><\/h2>\n\n\n\n<p>Understanding enantiomer-specific behavior is central to why chiral drug engineering matters. <em><strong>Suggestion:<\/strong> <mark style=\"background-color:rgba(0, 0, 0, 0);color:#d12727\" class=\"has-inline-color\">Open the mind map in a new tab and zoom out to view the complete structure clearly.<\/mark><\/em><\/p>\n\n\n\n<figure class=\"wp-block-image aligncenter size-large is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"560\" src=\"https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/11\/Science-Behind-Enantiomeric-Diff-1-1024x560.png\" alt=\"\" class=\"wp-image-9248\" style=\"width:726px;height:auto\" srcset=\"https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/11\/Science-Behind-Enantiomeric-Diff-1-1024x560.png 1024w, https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/11\/Science-Behind-Enantiomeric-Diff-1-300x164.png 300w, https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/11\/Science-Behind-Enantiomeric-Diff-1-768x420.png 768w, https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/11\/Science-Behind-Enantiomeric-Diff-1-1536x840.png 1536w, https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/11\/Science-Behind-Enantiomeric-Diff-1.png 1841w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><figcaption class=\"wp-element-caption\"><em>Why does one enantiomer behave differently from the other in biological systems?<br>Because biological targets are <strong>structurally chiral<\/strong>, giving rise to classic \u201chand-in-glove\u201d stereoselectivity.<\/em><\/figcaption><\/figure>\n\n\n\n<h5 class=\"wp-block-heading has-ast-global-color-0-color has-text-color has-link-color wp-elements-224c5ca54280c29a7d5d8d75db2322e6\"><strong>Pharmacodynamic Asymmetry<\/strong><\/h5>\n\n\n\n<p>Enantiomers may:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>bind with different affinities to receptors or enzymes,<\/li>\n\n\n\n<li>activate different signaling pathways, or<\/li>\n\n\n\n<li>behave as agonist vs. antagonist pairs.<\/li>\n<\/ul>\n\n\n\n<p>Example:<br><strong>S-ibuprofen<\/strong> is the analgesically active form, while <strong>R-ibuprofen<\/strong> is largely inactive but undergoes chiral inversion in vivo.<\/p>\n\n\n\n<h5 class=\"wp-block-heading has-ast-global-color-0-color has-text-color has-link-color wp-elements-5c989b5a44c2755989c2fd004303784a\"><strong>Pharmacokinetic Asymmetry<\/strong><\/h5>\n\n\n\n<p>Enantiomers may differ in:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>absorption rates,<\/li>\n\n\n\n<li>protein binding estimates,<\/li>\n\n\n\n<li>metabolism via enantioselective CYP pathways,<\/li>\n\n\n\n<li>renal or biliary excretion.<\/li>\n<\/ul>\n\n\n\n<p>Example:<br><strong>S-warfarin<\/strong> is 3\u20135 times more potent and metabolized mainly by CYP2C9, while <strong>R-warfarin<\/strong> uses CYP1A2 and CYP3A4\u2014leading to dramatically different half-lives and drug interactions.<\/p>\n\n\n\n<h5 class=\"wp-block-heading has-ast-global-color-0-color has-text-color has-link-color wp-elements-27772ee9b6870db15eb5bd8d31b36aee\"><strong>Toxicological Asymmetry<\/strong><\/h5>\n\n\n\n<p>Some notorious examples highlight this challenge:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>R-thalidomide<\/strong> is sedative; <strong>S-thalidomide<\/strong> is teratogenic.<\/li>\n\n\n\n<li>Certain <strong>beta-blocker enantiomers<\/strong> produce bradycardia while their mirror images do not.<\/li>\n<\/ul>\n\n\n\n<p>These asymmetries justify why chiral engineering is essential, not optional.<\/p>\n\n\n\n<p class=\"has-ast-global-color-0-color has-text-color has-link-color has-medium-font-size wp-elements-5b557b94e320467f28bdeedff99503cc\"><strong>Chiral Drug Engineering: The Core Approaches<\/strong><\/p>\n\n\n\n<h5 class=\"wp-block-heading has-ast-global-color-0-color has-text-color has-link-color wp-elements-514471767e7d86d8cadae72ca8b62ca7\"><strong>1. Asymmetric Synthesis: <\/strong>Engineering Chirality at the Molecular Level<\/h5>\n\n\n\n<p><strong>Asymmetric synthesis<\/strong> introduces chirality during drug formation rather than separating it afterward. Asymmetric synthesis allows chemists to build molecules in a way that preferentially forms one enantiomer over the other. This field is so impactful that it has been recognized twice by the <strong>Nobel Prize in Chemistry<\/strong>\u2014first in <strong>2001<\/strong> and again in <strong>2021<\/strong>.<\/p>\n\n\n\n<p>The <strong>2001 Nobel Prize in Chemistry<\/strong> was awarded to<strong> <\/strong>Ryoji Noyori, William S. Knowles, and K. Barry Sharpless for their pioneering contributions to <strong>asymmetric catalysis<\/strong>. Fast-forward twenty years. The <strong>2021 Nobel Prize in Chemistry<\/strong> went to Benjamin List and David W.C. MacMillan for creating <strong>asymmetric organocatalysis<\/strong>, a metal-free, environmentally friendly approach to stereoselective synthesis. Together, the 2001 and 2021 Nobel Prizes form the twin pillars of modern chiral drug engineering.<\/p>\n\n\n\n<h5 class=\"wp-block-heading has-ast-global-color-0-color has-text-color has-link-color wp-elements-3a294c54af8c7e5c8fffea19bd77aa04\"><strong>Key Techniques<\/strong><\/h5>\n\n\n\n<h5 class=\"wp-block-heading has-ast-global-color-0-color has-text-color has-link-color wp-elements-b086603c12bdd6a40add725aaacc64bf\">a. Chiral Catalysts<\/h5>\n\n\n\n<p>These catalysts create stereoselectivity without being consumed.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Chiral metal complexes<\/strong> (e.g., BINAP-Ru complexes in hydrogenations)<\/li>\n\n\n\n<li><strong>Organocatalysts<\/strong> like proline, cinchona alkaloids, and imidazolidinones<\/li>\n\n\n\n<li><strong>Biocatalysts<\/strong> (enzymes, engineered variants)<\/li>\n<\/ul>\n\n\n\n<p>The<em> Noyori asymmetric hydrogenation and Sharpless epoxidation<\/em> are Nobel-winning breakthroughs that revolutionized the field.<\/p>\n\n\n\n<h5 class=\"wp-block-heading has-ast-global-color-0-color has-text-color has-link-color wp-elements-e07b98466f5fcddfdebe4a05baff2d7e\">b. Chiral Auxiliarie<strong>s<\/strong><\/h5>\n\n\n\n<p>Temporary stereochemical guides attached to achiral substrates.<br>Dissociated after inducing asymmetry.<\/p>\n\n\n\n<p>Example: <em>Evans\u2019 oxazolidinone auxiliaries<\/em>\u2014widely used for setting stereocenters in \u03b2-hydroxy acids and peptides.<\/p>\n\n\n\n<h5 class=\"wp-block-heading has-ast-global-color-0-color has-text-color has-link-color wp-elements-8d521d5c3558bb309c368e2eac23f230\">c. Stereoselective Photochemical and Electrosynthetic Methods<\/h5>\n\n\n\n<p>Emerging fields that use light or electrons to drive enantioselective transformations.<\/p>\n\n\n\n<h5 class=\"wp-block-heading has-ast-global-color-0-color has-text-color has-link-color wp-elements-58a0ba584b8c613e0ce1de3401e526a3\">d. Flow-Assisted Asymmetric Synthesis<\/h5>\n\n\n\n<p>Continuous flow reactors allow rapid screening, improved heat\/mass transfer, and scalable stereoselective processes.<\/p>\n\n\n\n<h5 class=\"wp-block-heading has-ast-global-color-0-color has-text-color has-link-color wp-elements-0c5ed03c3ca07a74124985a16a94d591\"><strong>Why it matters<\/strong><\/h5>\n\n\n\n<p>Asymmetric synthesis reduces waste, lowers cost, scalability, avoids inactive\/toxic enantiomers, and ensures reproducible stereochemical purity.<\/p>\n\n\n\n<p class=\"has-ast-global-color-0-color has-text-color has-link-color wp-elements-7625d897f25d961b12f78f1e27f3cc79\"><strong><mark style=\"background-color:rgba(0, 0, 0, 0);color:#e12525\" class=\"has-inline-color\">Note<\/mark><\/strong>: For a comprehensive overview of Asymmetric Synthesis, see Chiralpedia\u2019s dedicated blog series &lt;<a href=\"https:\/\/chiralpedia.com\/blog\/tag\/chiral_resolution\/\" data-type=\"link\" data-id=\"https:\/\/chiralpedia.com\/blog\/tag\/chiral_resolution\/\">#Asymmetric_Synthesis&gt;<\/a>.<\/p>\n\n\n\n<h5 class=\"wp-block-heading has-ast-global-color-0-color has-text-color has-link-color wp-elements-8c81f42c0e777af66c110fa20f05e69c\"><strong>2. Chiral Resolution:<\/strong> Separating Enantiomers After Formation<\/h5>\n\n\n\n<p>When racemates form inevitably or unpredictably, <strong>chiral resolution<\/strong> enables isolation of desired enantiomers.<\/p>\n\n\n\n<h5 class=\"wp-block-heading has-ast-global-color-0-color has-text-color has-link-color wp-elements-2a1e71d241a82b4104871f65f8f14367\">a. Classical Resolution<\/h5>\n\n\n\n<p>Treating racemates with chiral acids or bases (e.g., tartaric acid, camphorsulfonic acid) to form diastereomeric salts with different solubilities.<\/p>\n\n\n\n<h5 class=\"wp-block-heading has-ast-global-color-0-color has-text-color has-link-color wp-elements-099752b214577c678be0b01c0a5e575f\">b. Chromatographic Resolution<\/h5>\n\n\n\n<p>Using <strong>chiral stationary phases (CSPs)<\/strong> in:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>HPLC<\/strong><\/li>\n\n\n\n<li><strong>SFC (supercritical fluid chromatography)<\/strong><\/li>\n\n\n\n<li><strong>GC (for volatile chiral compounds)<\/strong><\/li>\n<\/ul>\n\n\n\n<p>CSPs like amylose, cyclodextrins, or Pirkle phases exploit differential enantiomer\u2013phase interactions.<\/p>\n\n\n\n<h5 class=\"wp-block-heading has-ast-global-color-0-color has-text-color has-link-color wp-elements-328b910dadcb15b020ef5827927bf997\">c. Enzymatic Kinetic Resolution<\/h5>\n\n\n\n<p>Enzymes selectively react with one enantiomer.<br>For example, lipases esterify or hydrolyze a single enantiomer of secondary alcohols.<\/p>\n\n\n\n<h5 class=\"wp-block-heading has-ast-global-color-0-color has-text-color has-link-color wp-elements-574f601e0b72c5844c296122838d6721\">d. Dynamic Kinetic Resolution (DKR<em>)<\/em><\/h5>\n\n\n\n<p>Combines racemization of the slow-reacting enantiomer with selective enzymatic conversion\u2014ideally yielding up to <strong>100% theoretical yield<\/strong>.<\/p>\n\n\n\n<p class=\"has-ast-global-color-0-color has-text-color has-link-color wp-elements-ae9b5e268f9b6a4ad630dc247ea2397b\"><strong><mark style=\"background-color:rgba(0, 0, 0, 0);color:#de2424\" class=\"has-inline-color\">Note:<\/mark><\/strong> For expanded discussions on Chiral resolution, explore Chiralpedia\u2019s blog series &lt;<a href=\"https:\/\/chiralpedia.com\/blog\/tag\/chiral_resolution\/\" target=\"_blank\" rel=\"noreferrer noopener\">#Chiral_Resolution<\/a>&gt;.<\/p>\n\n\n\n<h5 class=\"wp-block-heading has-ast-global-color-0-color has-text-color has-link-color has-medium-font-size wp-elements-b5db5c21448664f06ebea2d4aad7c736\"><strong>3. Chiral Switch Strategy: Reinventing Existing Racemic Drugs<\/strong><\/h5>\n\n\n\n<p>Chiral switching is both a scientific and commercial strategy.<\/p>\n\n\n\n<h5 class=\"wp-block-heading has-ast-global-color-0-color has-text-color has-link-color wp-elements-f4b720f31172089b7e6f7d4b8ad4189b\">Why perform a chiral switch?<\/h5>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Reduce side effects associated with inactive enantiomers<\/li>\n\n\n\n<li>Improve therapeutic index<\/li>\n\n\n\n<li>Overcome metabolic variability<\/li>\n\n\n\n<li>Delay patent expiry (providing market exclusivity)<\/li>\n<\/ul>\n\n\n\n<h5 class=\"wp-block-heading has-ast-global-color-0-color has-text-color has-link-color wp-elements-c8c8b97438a1157aeddec75528e99978\">Successful Case studies<\/h5>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Esomeprazole<\/strong> (S-omeprazole) from omeprazole<\/li>\n\n\n\n<li><strong>Escitalopram<\/strong> (S-citalopram) from citalopram<\/li>\n\n\n\n<li><strong>Levalbuterol<\/strong> (R-albuterol) from albuterol<\/li>\n\n\n\n<li><strong>Dexlansoprazole<\/strong>, <strong>levocetirizine<\/strong>, <strong>dexmethylphenidate<\/strong><\/li>\n<\/ul>\n\n\n\n<p>Chiral switches often provide clinical advantages significant enough to justify the shift in practice.<\/p>\n\n\n\n<h5 class=\"wp-block-heading has-ast-global-color-0-color has-text-color has-link-color wp-elements-5e939f61ce27edfacc85bae6edea2651\">Engineering Considerations<\/h5>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Enantiomer-specific receptor binding<\/li>\n\n\n\n<li>Differential CYP-mediated metabolism<\/li>\n\n\n\n<li>Cleaner PK profiles<\/li>\n\n\n\n<li>Improved safety in special populations<\/li>\n<\/ul>\n\n\n\n<p>Chiral switches continue to be a fertile ground for innovation where racemic drugs still dominate.<\/p>\n\n\n\n<p><strong>Note:<\/strong> For a detailed treatment of Chiral Switch, visit the Chiralpedia blog series &lt;#<a href=\"https:\/\/chiralpedia.com\/blog\/chiral-switch-unlocking-the-potential-of-single-enantiomers\/\" data-type=\"link\" data-id=\"https:\/\/chiralpedia.com\/blog\/chiral-switch-unlocking-the-potential-of-single-enantiomers\/\">Chiral Switch<\/a>&gt;.<\/p>\n\n\n\n<figure class=\"wp-block-image aligncenter size-large is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"875\" src=\"https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/11\/Chiral-DE-Core-Approaches-2-1024x875.png\" alt=\"\" class=\"wp-image-9234\" style=\"width:708px;height:auto\" srcset=\"https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/11\/Chiral-DE-Core-Approaches-2-1024x875.png 1024w, https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/11\/Chiral-DE-Core-Approaches-2-300x256.png 300w, https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/11\/Chiral-DE-Core-Approaches-2-768x656.png 768w, https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/11\/Chiral-DE-Core-Approaches-2-1536x1312.png 1536w, https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/11\/Chiral-DE-Core-Approaches-2-2048x1749.png 2048w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><figcaption class=\"wp-element-caption\"><em><mark style=\"background-color:rgba(0, 0, 0, 0);color:#eb2f2f\" class=\"has-inline-color\">Chiral Drug Engineering: The Core Approaches<\/mark><\/em><br><br><em>A visual overview of the discussion on Chiral Drug Engineering: The core approaches is presented below as a concept map. <\/em><br><em><strong>Suggestion:<\/strong> <mark style=\"background-color:rgba(0, 0, 0, 0);color:#d12727\" class=\"has-inline-color\">Open the mind map in a new tab and zoom out to view the complete structure clearly.<\/mark><\/em><\/figcaption><\/figure>\n\n\n\n<p class=\"has-ast-global-color-0-color has-text-color has-link-color has-medium-font-size wp-elements-525797f045fcc6b27ceea2f7107b8c49\"><strong>Engineering Tools and Technologies Driving Modern Chiral Drug Development<\/strong><\/p>\n\n\n\n<h5 class=\"wp-block-heading\"><strong>1. Computational Chirality Engineering<\/strong><\/h5>\n\n\n\n<h5 class=\"wp-block-heading\">a. Quantum Chemical Methods<\/h5>\n\n\n\n<p>Predict stereochemical outcomes of reactions, transition states, and energetics.<\/p>\n\n\n\n<h5 class=\"wp-block-heading\">b. AI-Assisted Enantioselective Reaction Prediction<\/h5>\n\n\n\n<p>Machine learning models can now suggest optimal catalysts, solvents, and conditions for stereoselective reactions\u2014dramatically reducing experimental load.<\/p>\n\n\n\n<h5 class=\"wp-block-heading\">c. Molecular Docking and Dynamics<\/h5>\n\n\n\n<p>Simulate enantiomer-specific binding to receptors, enabling stereoselective drug design early in the pipeline.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h5 class=\"wp-block-heading\"><strong>2. Chiroptical and Analytical Technologies<\/strong><\/h5>\n\n\n\n<p>Fast, accurate enantiomeric characterization is the backbone of chiral engineering.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Chiral HPLC \/ SFC<\/strong><\/li>\n\n\n\n<li><strong>Vibrational Circular Dichroism (VCD)<\/strong><\/li>\n\n\n\n<li><strong>Electronic Circular Dichroism (ECD)<\/strong><\/li>\n\n\n\n<li><strong>NMR with chiral solvating agents<\/strong><\/li>\n\n\n\n<li><strong>Mass spectrometry for chiral metabolites<\/strong><\/li>\n<\/ul>\n\n\n\n<p>These tools ensure that every stereocenter is correctly assigned and controlled.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h5 class=\"wp-block-heading\"><strong>3. Enzyme Engineering and Biocatalysis<\/strong><\/h5>\n\n\n\n<p>Biocatalysis is reshaping stereochemistry.<\/p>\n\n\n\n<p>Genetically engineered enzymes\u2014via <strong>directed evolution<\/strong>, CRISPR-based editing, and computational sequence design\u2014achieve remarkable enantioselectivity in:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>hydroxylation<\/li>\n\n\n\n<li>epoxidation<\/li>\n\n\n\n<li>reductive amination<\/li>\n\n\n\n<li>carbon\u2013carbon bond formation<\/li>\n<\/ul>\n\n\n\n<p>Companies and academic labs now routinely evolve ketoreductases or transaminases specific to a single enantiomer.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h5 class=\"wp-block-heading\"><strong>4. Flow Chemistry and Process Intensification<\/strong><\/h5>\n\n\n\n<p>Continuous flow platforms enable:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>precise temperature control,<\/li>\n\n\n\n<li>rapid mixing,<\/li>\n\n\n\n<li>safer handling of reactive intermediates, and<\/li>\n\n\n\n<li>scalable stereoselective reactions.<\/li>\n<\/ul>\n\n\n\n<p>Flow-compatible chiral catalysts and immobilized enzymes further enhance efficiency.<\/p>\n\n\n\n<p class=\"has-ast-global-color-0-color has-text-color has-link-color has-medium-font-size wp-elements-0b37e7368157d25525e3c3cef2c2436d\"><strong>Case Studies: Chirality in Action<\/strong><\/p>\n\n\n\n<h5 class=\"wp-block-heading\"><strong>1. Esomeprazole<\/strong><\/h5>\n\n\n\n<figure class=\"wp-block-image aligncenter size-full is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"512\" height=\"378\" src=\"https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/11\/Omeprazole-enantiomers-4.png\" alt=\"\" class=\"wp-image-9207\" style=\"width:464px;height:auto\" srcset=\"https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/11\/Omeprazole-enantiomers-4.png 512w, https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/11\/Omeprazole-enantiomers-4-300x221.png 300w\" sizes=\"auto, (max-width: 512px) 100vw, 512px\" \/><figcaption class=\"wp-element-caption\"><mark style=\"background-color:rgba(0, 0, 0, 0);color:#da1818\" class=\"has-inline-color\">Omperazole<\/mark><br><em>The S-enantiomer of omeprazole provides higher and more consistent bioavailability and stronger acid suppression due to reduced first-pass metabolism.<\/em><\/figcaption><\/figure>\n\n\n\n<h5 class=\"wp-block-heading\"><strong>2. Levofloxacin<\/strong><\/h5>\n\n\n\n<figure class=\"wp-block-image aligncenter size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"458\" height=\"516\" src=\"https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/11\/Ofloxacin-Enantiomer.png\" alt=\"\" class=\"wp-image-9209\" srcset=\"https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/11\/Ofloxacin-Enantiomer.png 458w, https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/11\/Ofloxacin-Enantiomer-266x300.png 266w\" sizes=\"auto, (max-width: 458px) 100vw, 458px\" \/><figcaption class=\"wp-element-caption\"><mark style=\"background-color:rgba(0, 0, 0, 0);color:#d92929\" class=\"has-inline-color\">Ofloxacin Enantiomers<\/mark><br><em>The S-enantiomer of ofloxacin has greater antimicrobial activity and lower toxicity.<\/em><\/figcaption><\/figure>\n\n\n\n<h5 class=\"wp-block-heading\"><strong>3. L-Dopa<\/strong><\/h5>\n\n\n\n<p>Only the L-enantiomer can cross the blood\u2013brain barrier to treat Parkinson\u2019s disease\u2014one of the earliest triumphs of chirality in medicine.<\/p>\n\n\n\n<figure class=\"wp-block-image aligncenter size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"581\" height=\"180\" src=\"https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/11\/Dopa-enantiomers-1.png\" alt=\"\" class=\"wp-image-9218\" srcset=\"https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/11\/Dopa-enantiomers-1.png 581w, https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/11\/Dopa-enantiomers-1-300x93.png 300w\" sizes=\"auto, (max-width: 581px) 100vw, 581px\" \/><figcaption class=\"wp-element-caption\"><em>L-dopa, the (S)-enantiomer, is a chiral drug with one stereogenic center. It exists as a pair of enantiomers. The use of L-dopa resulted in reducing the required dose, and adverse effects. The pharmacological activity resides in the (S)-enantiomer where as the (R)-version harbors adverse effects. Hence, L-dopa is marketed as a<a href=\"https:\/\/en.wikipedia.org\/wiki\/Chiral_drugs\">&nbsp;unichiral drug&nbsp;<\/a>due to serious side-effect, granulocytopenia, attributable to the D-isomer.<\/em><\/figcaption><\/figure>\n\n\n\n<h5 class=\"wp-block-heading\"><strong>4. (S)-Metolachlor<\/strong><\/h5>\n\n\n\n<p>Outside pharma, this agricultural chiral switch reduced environmental load while improving herbicidal activity. <em>Its chemical structure, containing both <strong>central and axial chirality<\/strong>, generates four stereoisomers with markedly different biological properties.<\/em> S-Metolachlor is <strong>not a single pure stereoisomer<\/strong>, but a product <strong>enriched in the S configuration at the stereocenter<\/strong>. It contains mostly the two <strong>S-configured stereoisomers (S,M) and (S,P)<\/strong>.<\/p>\n\n\n\n<figure class=\"wp-block-image aligncenter size-full is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"454\" height=\"344\" src=\"https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/11\/Metalochlor-Journal.png\" alt=\"\" class=\"wp-image-9224\" style=\"width:506px;height:auto\" srcset=\"https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/11\/Metalochlor-Journal.png 454w, https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/11\/Metalochlor-Journal-300x227.png 300w\" sizes=\"auto, (max-width: 454px) 100vw, 454px\" \/><figcaption class=\"wp-element-caption\"><em>Metolachlor is one of the most widely used selective herbicides for pre- and post-emergent weed control in corn and other crops.  Over the last three decades, advances in stereoselective catalysis and environmental stewardship have driven a <strong>chiral switch<\/strong> from racemic metolachlor to an enantiomerically enriched commercial product, <strong>(S)-metolachlor<\/strong>, with substantially greater herbicidal potency and reduced environmental loading.<\/em><\/figcaption><\/figure>\n\n\n\n<p class=\"has-ast-global-color-0-color has-text-color has-link-color has-medium-font-size wp-elements-837ad536af82308462b90998bd584276\"><strong>The Future of Chiral Drug Engineering<\/strong><\/p>\n\n\n\n<p>The next decade will see rapid growth in:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>AI-driven enantioselective synthesis planning<\/strong><\/li>\n\n\n\n<li><strong>Biocatalytic cascades for multi-stereocenter molecules<\/strong><\/li>\n\n\n\n<li><strong>Chiral nanomaterials interacting stereoselectively with biological targets<\/strong><\/li>\n\n\n\n<li><strong>Stereodivergent catalysts controlling multiple chiral centers simultaneously<\/strong><\/li>\n\n\n\n<li><strong>Microbial fermentation for enantiopure API production<\/strong><\/li>\n<\/ul>\n\n\n\n<p>The boundary between chemistry, computation, and biology is blurring\u2014and chirality sits at the center of this convergence.<\/p>\n\n\n\n<p class=\"has-ast-global-color-0-color has-text-color has-link-color has-medium-font-size wp-elements-9e316c1999adbcade6b8c6749c3afcd7\"><strong>Conclusion<\/strong><\/p>\n\n\n\n<p>Chiral drug engineering is a prime example of how subtle features of molecular structure can profoundly influence human health. The journey from racemic mixtures to single-enantiomer precision has been shaped by scientific breakthroughs\u2014particularly the Nobel-recognized advances in asymmetric catalysis (2001) and organocatalysis (2021).<\/p>\n\n\n\n<p>By mastering molecular handedness, today\u2019s scientists can design medicines that are more selective, more effective, and safer than ever before. As tools grow smarter and more interdisciplinary, chiral engineering will continue to lead the transformation of modern therapeutics.<\/p>\n\n\n\n<p class=\"has-ast-global-color-0-color has-text-color has-link-color has-medium-font-size wp-elements-70f1e73667f2850b676b5e58240281c9\"><strong>References<\/strong><\/p>\n\n\n\n<h5 class=\"wp-block-heading\"><strong>Nobel Prizes<\/strong><\/h5>\n\n\n\n<ol class=\"wp-block-list\">\n<li>The Nobel Prize in Chemistry 2001 \u2013 Knowles, Noyori, Sharpless. <em>Chirally Catalyzed Hydrogenation and Oxidation Reactions.<\/em><br>Nobel Foundation. (Press Release, 10 October 2001).<\/li>\n\n\n\n<li>The Nobel Prize in Chemistry 2021 \u2013 List, MacMillan. <em>\u201cFor the development of asymmetric organocatalysis.\u201d<\/em><br>Nobel Foundation. (Press Release, 6 October 2021).<\/li>\n<\/ol>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h5 class=\"wp-block-heading\"><strong>Asymmetric Catalysis &amp; Organocatalysis<\/strong><\/h5>\n\n\n\n<ol start=\"3\" class=\"wp-block-list\">\n<li>Noyori, R. (2002). <em>Asymmetric Catalysis: Science and Opportunities.<\/em> Angewandte Chemie International Edition, 41(12), 2008\u20132022.<\/li>\n\n\n\n<li>Knowles, W. S. (2002). <em>Asymmetric Hydrogenations (Nobel Lecture).<\/em><strong> <\/strong>Angewandte Chemie International Edition, 41<strong>(1<\/strong>2), 1998\u20132007.<\/li>\n\n\n\n<li>Sharpless, K. B.<strong> <\/strong>(2002). <em>Searching for New Reactivity (Nobel Lecture).<\/em> Angewandte Chemie International Edition, 41(12), 2024\u20132032.<\/li>\n\n\n\n<li>List, B. (2021). <em>The Development of Asymmetric Organocatalysis (Nobel Lecture).<\/em> Angewandte Chemie International Edition, 60(36), 18650\u201318665.<\/li>\n\n\n\n<li>MacMillan, D. W. C. (2021). <em>The Advent and Impact of Organocatalysis (Nobel Lecture).<\/em> Angewandte Chemie International Edition, 60(36), 18686\u201318703.<\/li>\n\n\n\n<li><a href=\"https:\/\/chiralpedia.com\/blog\/tag\/asymmetric_synthesis\/\">https:\/\/chiralpedia.com\/blog\/tag\/asymmetric_synthesis\/<\/a><\/li>\n<\/ol>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h5 class=\"wp-block-heading\"><strong>General Chirality &amp; Single-Enantiomer Drug References<\/strong><\/h5>\n\n\n\n<ol start=\"8\" class=\"wp-block-list\">\n<li>Nguyen, L. A. (2006). <em>Chiral Drugs: An Overview.<\/em> International Journal of Biomedical Science, <strong>2<\/strong>(2), 85\u2013100.<\/li>\n\n\n\n<li>Ari\u00ebns, E. J. (1984). <em>Stereochemistry, a Basis for Sophisticated Nonsense in Pharmacokinetics and Clinical Pharmacology.<\/em><br>European Journal of Clinical Pharmacology, 26(6), 663\u2013668.<\/li>\n\n\n\n<li>Agranat, I. D., Caner, H., &amp; Caldwell, J. (2002). <em>Molecular and Clinical Aspects of Chiral Switches: Therapeutic Advantages of Single-Enantiomer Drugs. <\/em>Nature Reviews Drug Discovery, 1(10), 753\u2013768.<\/li>\n\n\n\n<li>Calcaterra, A., &amp; D\u2019Acquarica, I. (2018). <em>The Market of Chiral Drugs: Chiral Switches Versus De Novo Enantiopure Compounds.<\/em><br>Journal of Pharmaceutical and Biomedical Analysis, 147, 323\u2013340.<\/li>\n<\/ol>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h5 class=\"wp-block-heading\"><strong>Drug Examples &amp; Stereoselective Pharmacology<\/strong><\/h5>\n\n\n\n<ol start=\"12\" class=\"wp-block-list\">\n<li>Walle, T. (2000). <em>Stereochemical Differences in the Pharmacokinetics and Pharmacodynamics of Beta-Blockers.<\/em><br>Clinical Pharmacokinetics, 38(2), 79\u201388.<\/li>\n\n\n\n<li>Andersson, T., et al. (2001). <em>Pharmacokinetics and Pharmacodynamics of Esomeprazole, the S-Isomer of Omeprazole.<\/em><br>Clinical Pharmacokinetics, 40(6), 411\u2013426.<\/li>\n\n\n\n<li>Ward, T. J., &amp; Baker, B. A. (2008). <em>Chiral Separations.<\/em> Analytical Chemistry, 80(12), 4363\u20134372. <\/li>\n\n\n\n<li>Hoffman, R. S. (2001). <em>Warfarin: Pharmacokinetics and Pharmacodynamics of Enantiomers.<\/em> Journal of Thrombosis and Thrombolysis, 12(1), 7\u201316.<\/li>\n\n\n\n<li>Peresypkina, E. V., et al. (2017). <em>Enantioselective Toxicity and Pharmacokinetics of Chiral Drugs.<\/em> Current Drug Metabolism, 18(7), 608\u2013621.<\/li>\n<\/ol>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h5 class=\"wp-block-heading\"><strong>Biocatalysis &amp; Enzymatic Methods<\/strong><\/h5>\n\n\n\n<ol start=\"17\" class=\"wp-block-list\">\n<li>Bornscheuer, U. T., et al. (2012). <em>Engineering the Third Wave of Biocatalysis.<\/em> Nature, 485(7397), 185\u2013194.<\/li>\n\n\n\n<li>Arnold, F. H. (2019). <em>Innovation by Directed Evolution (Nobel Lecture).<\/em> Angewandte Chemie International Edition, 58(41), 14420\u201314426.<\/li>\n<\/ol>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h5 class=\"wp-block-heading\"><strong>Analytical &amp; Chiroptical Methods<\/strong><\/h5>\n\n\n\n<ol start=\"19\" class=\"wp-block-list\">\n<li>L\u00f3pez, C., et al. (2019). <em>Advances in Chiral Chromatography for Pharmaceutical Analysis.<\/em> TrAC Trends in Analytical Chemistry, 120, 115660.<\/li>\n\n\n\n<li>Stephens, P. J., Devlin, F. J., &amp; Pan, J.-J. (2008). <em>The Determination of Absolute Configuration Using Vibrational Circular Dichroism (VCD).<\/em> Chemical Reviews, 108(9), 2854\u20132871.<\/li>\n<\/ol>\n\n\n\n<figure class=\"wp-block-embed is-type-wp-embed is-provider-chiralpedia wp-block-embed-chiralpedia\"><div class=\"wp-block-embed__wrapper\">\n<blockquote class=\"wp-embedded-content\" data-secret=\"4yxI22aTiU\"><a href=\"https:\/\/chiralpedia.com\/blog\/chiral-drugs-a-twisted-tale-in-pharmaceuticals\/\">Chiral Drugs: A twisted tale in pharmaceuticals<\/a><\/blockquote><iframe loading=\"lazy\" class=\"wp-embedded-content\" sandbox=\"allow-scripts\" security=\"restricted\" style=\"position: absolute; visibility: hidden;\" title=\"&#8220;Chiral Drugs: A twisted tale in pharmaceuticals&#8221; &#8212; Chiralpedia\" src=\"https:\/\/chiralpedia.com\/blog\/chiral-drugs-a-twisted-tale-in-pharmaceuticals\/embed\/#?secret=LjIFNgMw3Q#?secret=4yxI22aTiU\" data-secret=\"4yxI22aTiU\" width=\"500\" height=\"282\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\"><\/iframe>\n<\/div><\/figure>\n\n\n\n<figure class=\"wp-block-embed is-type-wp-embed is-provider-chiralpedia wp-block-embed-chiralpedia\"><div class=\"wp-block-embed__wrapper\">\n<blockquote class=\"wp-embedded-content\" data-secret=\"wToWif4odP\"><a href=\"https:\/\/chiralpedia.com\/blog\/understanding-the-fundamentals-of-asymmetric-synthesis\/\">Understanding the Fundamentals of Asymmetric Synthesis<\/a><\/blockquote><iframe loading=\"lazy\" class=\"wp-embedded-content\" sandbox=\"allow-scripts\" security=\"restricted\" style=\"position: absolute; visibility: hidden;\" title=\"&#8220;Understanding the Fundamentals of Asymmetric Synthesis&#8221; &#8212; Chiralpedia\" src=\"https:\/\/chiralpedia.com\/blog\/understanding-the-fundamentals-of-asymmetric-synthesis\/embed\/#?secret=XpGsVNp4oI#?secret=wToWif4odP\" data-secret=\"wToWif4odP\" width=\"500\" height=\"282\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\"><\/iframe>\n<\/div><\/figure>\n\n\n\n<figure class=\"wp-block-embed is-type-wp-embed is-provider-chiralpedia wp-block-embed-chiralpedia\"><div class=\"wp-block-embed__wrapper\">\n<blockquote class=\"wp-embedded-content\" data-secret=\"aT5Wa12LZj\"><a href=\"https:\/\/chiralpedia.com\/blog\/chiral-switch-unlocking-the-potential-of-single-enantiomers\/\">Chiral Switch: Unlocking the Potential of Single Enantiomers<\/a><\/blockquote><iframe loading=\"lazy\" class=\"wp-embedded-content\" sandbox=\"allow-scripts\" security=\"restricted\" style=\"position: absolute; visibility: hidden;\" title=\"&#8220;Chiral Switch: Unlocking the Potential of Single Enantiomers&#8221; &#8212; Chiralpedia\" src=\"https:\/\/chiralpedia.com\/blog\/chiral-switch-unlocking-the-potential-of-single-enantiomers\/embed\/#?secret=UkVQzlGp5l#?secret=aT5Wa12LZj\" data-secret=\"aT5Wa12LZj\" width=\"500\" height=\"282\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\"><\/iframe>\n<\/div><\/figure>\n\n\n\n<p>Buser, H.-R.; Poiger, T.; M\u00fcller, M. D. <em>Enantioselective Determination of Chiral Pesticides in Environmental Matrices Using Enantioselective GC and HPLC<\/em>. Environmental Science &amp; Technology, 2000, 34 (5), 2690-2696.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Where a molecule\u2019s handedness meets clever engineering\u2014shaping safer, more precise, and more effective medicines. Introduction: Why Chirality Matters in Drug Engineering In the world of drug design, a subtle twist in molecular geometry can change everything. Two molecules may share the same atoms and bonding pattern yet behave like entirely different substances simply because they are arranged as non-superimposable mirror images\u2014enantiomers. This property, known as chirality, is one of the most critical yet nuanced dimensions &hellip;<\/p>\n<p class=\"read-more\"> <a class=\"\" href=\"https:\/\/chiralpedia.com\/blog\/chiral-drug-engineering-designing-safer-smarter-and-more-selective-medicines\/\"> <span class=\"screen-reader-text\">Chiral Drug Engineering: Building Safer, Smarter, and More Selective Medicines<\/span> Read More &raquo;<\/a><\/p>\n","protected":false},"author":1,"featured_media":9256,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"","site-content-layout":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","footnotes":""},"categories":[7],"tags":[23,29,107,100,22,67],"ppma_author":[93],"class_list":["post-9160","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-chiral-science","tag-chiral_drugs","tag-chiral_separation","tag-chiral_switch","tag-chiral_synthesis","tag-chirality","tag-chiralpedia"],"authors":[{"term_id":93,"user_id":1,"is_guest":0,"slug":"chiralusrblg","display_name":"Valliappan Kannappan","avatar_url":{"url":"https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2024\/09\/vk.jpg","url2x":"https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2024\/09\/vk.jpg"},"first_name":"","last_name":"","user_url":"https:\/\/chiralpedia.com\/blog\/","job_title":"Founder, chiralpedia.com","description":""}],"_links":{"self":[{"href":"https:\/\/chiralpedia.com\/blog\/wp-json\/wp\/v2\/posts\/9160","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/chiralpedia.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/chiralpedia.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/chiralpedia.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/chiralpedia.com\/blog\/wp-json\/wp\/v2\/comments?post=9160"}],"version-history":[{"count":40,"href":"https:\/\/chiralpedia.com\/blog\/wp-json\/wp\/v2\/posts\/9160\/revisions"}],"predecessor-version":[{"id":9261,"href":"https:\/\/chiralpedia.com\/blog\/wp-json\/wp\/v2\/posts\/9160\/revisions\/9261"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/chiralpedia.com\/blog\/wp-json\/wp\/v2\/media\/9256"}],"wp:attachment":[{"href":"https:\/\/chiralpedia.com\/blog\/wp-json\/wp\/v2\/media?parent=9160"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/chiralpedia.com\/blog\/wp-json\/wp\/v2\/categories?post=9160"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/chiralpedia.com\/blog\/wp-json\/wp\/v2\/tags?post=9160"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/chiralpedia.com\/blog\/wp-json\/wp\/v2\/ppma_author?post=9160"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}